Details for New Drug Application (NDA): 209633
✉ Email this page to a colleague
The generic ingredient in TOFACITINIB CITRATE is tofacitinib citrate. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.
Summary for 209633
| Tradename: | TOFACITINIB CITRATE |
| Applicant: | Breckenridge |
| Ingredient: | tofacitinib citrate |
| Patents: | 0 |
Pharmacology for NDA: 209633
| Mechanism of Action | Janus Kinase Inhibitors |
Suppliers and Packaging for NDA: 209633
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TOFACITINIB CITRATE | tofacitinib citrate | TABLET;ORAL | 209633 | ANDA | Breckenridge Pharmaceutical, Inc. | 51991-329 | 51991-329-06 | 60 TABLET in 1 BOTTLE (51991-329-06) |
| TOFACITINIB CITRATE | tofacitinib citrate | TABLET;ORAL | 209633 | ANDA | Breckenridge Pharmaceutical, Inc. | 51991-963 | 51991-963-06 | 60 TABLET in 1 BOTTLE (51991-963-06) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Jun 3, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Jun 3, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
